Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Health

>> AMGEN Latest News

MAR 02, 2015 - Seattle Times

A Must Read - Share

Amgen says study finds its cancer drug tops rival’s

The study found that patients treated with Kyprolis after a second onset of multiple myeloma lived twice as long as those treated with Velcade, a drug marketed by Johnson & Johnson and Takeda Pharmaceutical, Amgen said.

Tags: Amgen says study finds its cancer drug tops rival’s,  Amgen Latest News

MAR 01, 2015 - Wall Street Journal

A Must Read - Share

Amgen Sees Positive Results From Kyprolis Study

Amgen took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.

Tags: Amgen Sees Positive Results From Kyprolis Study,  Amgen Latest News

MAR 01, 2015 - Yahoo! News

A Must Read - Share

Amgen says Kyprolis doubles progression-free survival vs Velcade

Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. Kyprolis, the centerpiece of Amgen's nearly $10 billion acquisition of Onyx Pharmaceuticals in 2013, had sales last year of $331 million. Velcade, sold ...

Tags: Amgen says Kyprolis doubles progression-free survival vs Velcade,  Amgen Latest News

FEB 25, 2015 - Wall Street Journal

A Must Read - Share

Amgen Drug Shows Positive Results in Late-Phase Study

A late-phase clinical study of Amgen Inc.’s experimental treatment for secondary hyperparathyroidism in patients with chronic kidney disease showed a higher percentage of patients responded to its treatment.

Tags: Amgen Drug Shows Positive Results in Late-Phase Study,  Amgen Latest News